Expression of Ezrin,HGF,C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats

被引:7
|
作者
Xing-Guo Tan and Zhu-Lin Yang Research Laboratory of Hepatobiliary Diseases
机构
关键词
pancreatic neoplasms; animal model; Ezrin; hepatocyte growth factor; C-met;
D O I
暂无
中图分类号
R735.9 [胰腺肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND:Recent studies have confirmed that the expression of Ezrin,hepatocyte growth factor(HGF)and its receptor(C-met)is related to the genesis,progress,invasion and metastasis of some malignant tumors.Researches have also found that the biological function of Ezrin is closely related to HGF/C-met in malignant tumors.However,there is no report on the expression levels of Ezrin,HGF and C-met in rat pancreatic cancer induced by dimethylbenzanthracene (DMBA).This study aimed to detect the expression of Ezrin, HGF and C-met in rat pancreatic cancer and non-cancerous pancreatic tissues,and assess its effect in cancer induction by DMBA. METHODS:Ninety Sprague-Dawley rats were divided into 3 groups randomly:40 in a pancreatic cancer model group (group A),40 in a trichostatin A(TSA)intervention group (group B),and 10 in a control group(group C).DMBA was directly implanted into the parenchyma of rat pancreas in group A+group B.The rats of group B were treated with 1 ml of TSA saline solution(1μg/ml)via intraperitoneal injection weekly.The carcinogenesis of rats executed within 3-5 months in groups A and B was observed by macrograph and microscopy. Meanwhile,the rats in group C were executed within 5 months. The EnVision TM immunohistochemistry for detecting the expression levels of Ezrin,HGF and C-met was used in paraffinembedded sections of the pancreatic specimens. RESULTS:The incidence of pancreatic cancer in group A was 48.6%and in group B 33.3%.The maximal diameter of tumor mass was significantly larger in group A than that in group B(P<0.05).No pathological changes were observed , in the pancreas of group C and other main organs of groups A and B.The positive rates of Ezrin,HGF and C-met were significantly higher in ductal adenocarcinoma than in non- cancerous pancreatic tissues of groups A and B(P<0.01).The positive rates of Ezrin,HGF and C-met were significantly higher in ductal adenocarcinoma of group A than those in non- cancerous pancreatic tissues of group A(P<0.05),but there was no significant difference in group B(P>0.05).The positive rates of Ezrin,HGF and C-met in non-cancerous pancreatic tissues proved mild to severe atypical hyperplasia of the ductal epithelia.The pancreas of group C and 2 cases of fibrosarcoma showed the negative expression of Ezrin,HGF and C-met.There was a trend of consistency in the expression of Ezrin,HGF and C-met in ductal adenocarcinoma(P<0.05 or P<0.01). CONCLUSIONS:DMBA directly implanted into the parenchyma of the pancreas can produce a model of pancreatic cancer with a high incidence in a short time.TSA might inhibit the carcinogenesis and growth of pancreatic cancer,and its effects may be related to the inhibition of the expression of Ezrin,HGF and C-met during the process.Ezrin,HGF and C-met may have positive effects on the carcinogenesis of rat pancreas.
引用
收藏
页码:639 / 644
页数:6
相关论文
共 50 条
  • [41] Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer
    Avan, Amir
    Quint, Karl
    Nicolini, Francesco
    Funel, Niccola
    Frampton, Adam E.
    Maftouh, Mina
    Pelliccioni, Serena
    Schuurhuis, Gerrit J.
    Peters, Godefridus J.
    Giovannetti, Elisa
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (05) : 940 - 950
  • [42] c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
    Daniel Delitto
    Eva Vertes-George
    Steven J Hughes
    Kevin E Behrns
    Jose G Trevino
    World Journal of Gastroenterology, 2014, (26) : 8458 - 8470
  • [43] HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
    Fu, Jianjiang
    Su, Xiaorui
    Li, Zhihua
    Deng, Ling
    Liu, Xiawei
    Feng, Xuancheng
    Peng, Juan
    ONCOGENE, 2021, 40 (28) : 4625 - 4651
  • [44] Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer
    Boromand, Nadia
    Hasanzadeh, Malihe
    ShahidSales, Soodabeh
    Farazestanian, Marjaneh
    Gharib, Masoumeh
    Fiuji, Hamid
    Behboodi, Negin
    Ghobadi, Niloofar
    Hassanian, Seyed Mahdi
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (06) : 4490 - 4496
  • [45] Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Rongdang Fu
    Shaotao Jiang
    Jieyuan Li
    Huanwei Chen
    Xiaohong Zhang
    Medical Oncology, 2020, 37
  • [46] Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer
    Fu, Le
    Guo, Wei
    Liu, Bingshan
    Sun, Linlin
    Bi, Zhenghong
    Zhu, Li
    Wang, Xinyan
    Liu, Bin
    Xie, Qian
    Li, Ke
    BIOMARKERS, 2013, 18 (02) : 126 - 135
  • [47] Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang
    Jiang, Shaotao
    Li, Jieyuan
    Chen, Huanwei
    Zhang, Xiaohong
    MEDICAL ONCOLOGY, 2020, 37 (04)
  • [48] Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers
    Hiscox, SE
    Hallett, MB
    Puntis, MCA
    Nakamura, T
    Jiang, WG
    CANCER INVESTIGATION, 1997, 15 (06) : 513 - 521
  • [49] c-MET and HGF mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival
    Ang, Celina Su-Ping
    Sun, Mark Yipin
    Fidel Huitzil-Melendez, David
    Chou, Joanne Fu-Lou
    Capanu, Marinela
    Jarnagin, William
    Fong, Yuman
    Dematte, Ronald Paul
    D'Angelica, Michael
    Allen, Peter
    Chen, Chin-Tung
    O'Reilly, Eileen Mary
    Weiser, Martin Ross
    Abou-Alfa, Ghassan Khaled
    ANTICANCER RESEARCH, 2013, 33 (08) : 3241 - 3245
  • [50] Co-expression of VEGF, c-Met and HGF/SF in secondary pleural tumors
    Naim, R
    Tolnay, E
    Mueller, KM
    Kuhnen, C
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2004, 14 (05) : 787 - 791